RxDoctor Payments Data

Gina Chandler, MD

Cardiovascular Disease · Nashville, TNNPI 1093706962

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 92 payments — averaging $22.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$555
  • Amgen$206
  • Abiomed$193
  • E.r. Squibb & Sons, L.L.C.$163
  • AstraZeneca$147
  • Actelion Pharmaceuticals US, Inc.$144
  • plus $686 from 15 others

What the payments were for

  • Food & beverage$2,04798%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,093 in reported general payments places this provider in the 45th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$70,334
Medicare patients
335
Services billed
900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$223,563
XareltoRivaroxaban96$120,252
EntrestoSacubitril/Valsartan67$80,004
FarxigaDapagliflozin Propanediol28$37,356
JardianceEmpagliflozin11$17,798
Repatha SureclickEvolocumab14$14,758
Praluent PenAlirocumab12$14,209
Metoprolol Succinate283$4,306
Diltiazem 12hr ErDiltiazem Hcl21$3,473
Atorvastatin Calcium319$3,460
Nebivolol Hcl50$3,337
Losartan Potassium196$2,257
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid31$2,221
Amiodarone Hcl59$2,142
Flecainide Acetate37$2,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$223,563194 claims
Johnson & JohnsonXarelto$555$120,25296 claims
NovartisEntresto$42$80,00467 claims
AstraZenecaFarxiga$147$37,35628 claims
Boehringer IngelheimJardiance$52$17,79811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →